SCHEMBL1922201

SCHEMBL1922201

CC(Br)C(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.55
TSHR P16473 1/20 0.55
CASP1 P29466 1/20 0.55
ALDH1A1 P00352 6/20 0.50
MAPK1 P28482 1/20 0.50
HIF1A Q16665 1/20 0.50
GAA P10253 1/20 0.49
MAPT P10636 3/20 0.49
KDM4E B2RXH2 1/20 0.49
POLB P06746 3/20 0.46
THRB P10828 1/20 0.46
RECQL P46063 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ALOX12 P18054 1/20 0.46
RAB9A P51151 4/20 0.45
CYP3A4 P08684 1/20 0.45
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1921942 0.86 SMN1; SMN2 (0.52) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL30173716 0.86 SMN1; SMN2 (0.52) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL29712852 0.85 ALDH1A1 (0.55) SMN1; SMN2TSHRCASP1ALDH1A1MAPT
SCHEMBL3141276 0.85 ALDH1A1 (0.55) SMN1; SMN2TSHRCASP1ALDH1A1MAPT
SCHEMBL30209768 0.85 SMN1; SMN2 (0.59) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL8196836 0.85 SMN1; SMN2 (0.59) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL11408672 0.85 TSHR (0.59) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL1922910 0.84 MAPK1 (0.46) TSHRALDH1A1MAPK1MAPTPOLB
SCHEMBL8545021 0.84 FLT1 (0.45) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL8395051 0.84 FLT1 (0.45) SMN1; SMN2TSHRCASP1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10398028-B2 Surface treating composition for copper and copper alloy and utilization thereof SHIKOKU CHEMICALS CORPORATION (JP) 2019-08-27 US disclosed
US-20170064823-A1 SURFACE TREATING COMPOSITION FOR COPPER AND COPPER ALLOY AND UTILIZATION THEREOF SHIKOKU CHEMICALS CORPORATION (JP) 2017-03-02 US disclosed
US-9532493-B2 Surface treating composition for copper and copper alloy and utilization thereof SHIKOKU CHEMICALS CORPORATION (JP) 2016-12-27 US disclosed
CN-103547706-B Surface treatment composition for copper and copper alloy and use thereof 四国化成工业株式会社 2016-09-28 CN disclosed
EP-2714962-B1 SURFACE TREATING COMPOSITION FOR COPPER AND COPPER ALLOY AND UTILIZATION THEREOF SHIKOKU CHEM (JP) 2015-07-08 EP disclosed
US-20140097231-A1 SURFACE TREATING COMPOSITION FOR COPPER AND COPPER ALLOY AND UTILIZATION THEREOF SHIKOKU CHEMICALS CORPORATION (JP) 2014-04-10 US disclosed
WO-2012161341-A1 SURFACE TREATING COMPOSITION FOR COPPER AND COPPER ALLOY AND UTILIZATION THEREOF SHIKOKU CHEMICALS CORPORATION (JP) 2012-11-29 WO disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 US disclosed
US-5602132-A USEFUL IN TREATMENT OF PATHOLOGIES INVOLVING CORTICOTROPIN RELEASING FACTOR SANOFI (FR) 1997-02-11 US disclosed
WO-1997000868-A1 4-PHENYLAMINOTHIAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES SANOFI (FR) 1997-01-09 WO disclosed
CN-1127252-A Branched-amino-sbustituted thiazoles, processes for their preparation and the pharmaceutical compositions which contain them SANOFI SA (FR) 1996-07-24 CN disclosed
US-5464847-A Moduators of corticotropin releasing factor ELF SANOFI (FR) 1995-11-07 US disclosed
EP-0659747-A1 Branched aminothiazole derivatives process for their preparation and pharmaceutical compositions containing them SANOFI (FR) 1995-06-28 EP disclosed
EP-0576350-A1 Branched alkylamino thiozole derivatives, process for their preparation and pharmaceutical compositions containing them SANOFI (FR) 1993-12-29 EP disclosed
EP-0207590-B1 SUBSTITUTED AZOLYL ETHANOL DERIVATIVES AS PLANT GROWTH REGULATORS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-01-15 EP disclosed
US-4871389-A PLANT GROWTH REGULATORS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-10-03 US disclosed
US-4690931-A IN TREATMENT OF ANOXIA OR BRAIN DAMAGE SYNTHELABO (FR) 1987-09-01 US disclosed
EP-0207590-A2 Substituted azolyl ethanol derivatives as plant growth regulators IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10398028-B2 Surface treating composition for copper and copper alloy and utilization thereof SOD1, SOD3, AOC3 SMN1; SMN2 310/4885TSHR 2687/4885CASP1 3940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.